- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
FDA Approves Terbinafine (Lamisil) Granules for Tinia Capitis in Kids
ROCKVILLE, Md. -- The FDA has approved terbinafine oral granules (Lamisil), which can be sprinkled on food, for treatment of tinea capitis in children four years and older.
ROCKVILLE, Md., Oct. 2 -- The FDA has approved terbinafine oral granules (Lamisil), which can be sprinkled on food, for tinia capitis in children four years and older.
The FDA said it asked Novartis to develop a "palatable formulation" for use in children against ringworm. In response, the company developed the easy-to-swallow granules.
The approved pediatric doses, recommended for six weeks, were determined through clinical trials in children, the FDA said. The actual dosage amount will be determined by the weight of the child.
Steven Galson, M.D., M.P.H., director of the FDA's Center for Drug Evaluation and Research, said tinea capitis "is a persistent infection that is hard to treat and one that causes children embarrassment."
Oral terbinafine is approved for treatment of toenail or fingernail fungus caused by susceptible dermatophytes and topical terbinafine is approved in over-the-counter formulations for treatment of tinea pedis, tinea cruris, and tinea corporis, and in prescription formulation for tinea versicolor in adults.
